



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Eohilia (budesonide suspension) Page: 1 of 2

Effective Date: 2/11/2026 Last Review Date: 1/2026

Applies to: Illinois New Jersey Pennsylvania Kids
 Maryland Florida Kids Virginia

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Eohilia (budesonide suspension) under the patient's prescription drug benefit.

Description:

FDA-Approved Indication

Eohilia is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).

Limitations of Use

Eohilia has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks.

Applicable Drug List:

Eohilia

Policy/Guideline:

Criteria for Approval:

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient has the diagnosis of eosinophilic esophagitis (EoE). Documentation is required for approval.

AND

- The patient is 11 years of age or older

AND

- The request is NOT for continuation of therapy

AND

- The patient has a history of clinical symptoms of esophageal dysfunction (e.g., eating problems, abdominal pain, heartburn, dysphagia, vomiting, food impaction, weight loss) at baseline

OR

- The request is for continuation of therapy

AND

- The patient has achieved or maintained a positive clinical response (e.g., improvement in symptoms of esophageal dysfunction, histologic remission on biopsy). [Documentation is required for approval.]



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Eohilia (budesonide suspension) Page: 2 of 2

Effective Date: 2/11/2026 Last Review Date: 1/2026

Applies to: Illinois New Jersey Pennsylvania Kids
 Maryland Florida Kids Virginia

Approval Duration and Quantity Restrictions:

Initial Approval: 6 months

Renewal Approval: 12 months

Quantity Level Limit: 60 single-dose stick packs per 30 days

References:

1. Eohilia [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; January 2025.
2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed August 11, 2025.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 08/11/2025).
4. Dellon E, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). *Am J Gastroenterol*. 2013;108(5):679–692.
5. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(6):1776-1786.
6. Hirano I, Collins MH, Katzka DA, et al. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. *Clin Gastroenterol Hepatol*. 2022;20(3):525-534.e10.
7. Warzecha J, Dziekiewicz M, Bienkowska-Tokarczyk A, et al. A New Viscous Budesonide Formulation for the Treatment of Eosinophilic Esophagitis in Children: A Preliminary Experience and Review of the Literature. *J Clin Med*. 2022;11(22):6730.